Stock LGVN LONGEVERON INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Longeveron Inc.

Equities

LGVN

US54303L2034

Market Closed - Nasdaq
Other stock markets
 01:30:00 09/05/2024 am IST 		5-day change 1st Jan Change
1.66 USD -1.19% Intraday chart for Longeveron Inc. -4.60% -87.79%
30/04 Longeveron Files Prospectus for Secondary Offering MT
15/04 Top Premarket Gainers MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Top Premarket Gainers
MT
Longeveron to Effect 1-for-10 Reverse Stock Split
MT
Longeveron Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Longeveron Receives Notice of United States Patent Allowance for the Technology Behind Its Lead Investigation Product Lomecel-B
CI
Longeveron Announces Additional Positive Clinical Data and Imaging Biomarker Results from the Clear Mind Phase 2A Trial of Lomecel-B? in the Treatment of Mild Alzheimer?S Disease
CI
Long-Term Survival Data from Longeveron?s Elpis 1 Trial Presented At the 2023 Scientific Sessions of the American Heart Association
CI
Earnings Flash (LGVN) LONGEVERON Posts Q3 Revenue $150,000
MT
Longeveron Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Longeveron Inc. Featured in Syndicated Broadcast Highlighting Top-Line Results from Clear MIND Phase 2a Clinical Trial of Lomecel-B?? for the Treatment of Mild Alzheimer's
CI
Longeveron Inc. Announces Positive Top-Line Results for Lomecel-B in Its Clear Mind Phase 2A Clinical Trial in the Treatment of Mild Alzheimer?s Disease
CI
Longeveron Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Earnings Flash (LGVN) LONGEVERON Reports Q2 Revenue $217,000
MT
Longeveron Inc Announces Achievement of Surpassing 50% Enrollment Threshold in Phase 2 ELPIS II Study of Lomecel-B? in Hypoplastic Left Heart Syndrome
CI
Companies in Alzheimer's race after US nod for Eisai/Biogen drug
RE
Longeveron Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Earnings Flash (LGVN) LONGEVERON Reports Q1 Revenue $279,000, vs. Street Est of 150,000
MT
Longeveron Inc Announces New Long-Term Survival Data from ELPIS I Trial of Lomecel-B™ for Hypoplastic Left Heart Syndrome
CI
LONGEVERON INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)
AQ
Longeveron Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022
CI
Longeveron Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LGVN Stock
  4. News Longeveron Inc.
  5. Highlights
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW